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CASE REPORT Open Access
Type 1 interferonopathy presenting as
juvenile idiopathic arthritis with interstitial
lung disease: report of a new phenotype
S. L. N. Clarke1,2, L. Robertson3, G. I. Rice4, L. Seabra5, T. N. Hilliard6, Y. J. Crow5,7 and A. V. Ramanan1,8*
Abstract
Background: STING-associated vasculopathy with onset in infancy (SAVI) is a type 1 interferonopathy manifesting
as a pulmonary and vascular syndrome resulting from gain-of-function mutations in TMEM173, the gene encoding
STING. Familial reports in the literature are sparse.
Case presentation: We report a case series of SAVI in a three generation kindred, with a phenotype of interstitial
lung disease (ILD) and rheumatoid factor positive polyarticular juvenile idiopathic arthritis (JIA). Current and
historical medical records were reviewed for clinical and laboratory information. Whole blood from cases 1 and 2,
plus stored appendicectomy tissue from case 3, underwent DNA sequencing of the TMEM173 gene. Peripheral
blood RNA was obtained from cases 1 and 2 for functional assessment of the TMEM173 mutation. DNA sequencing
identified the same heterozygous TMEM173 mutation (c.463G > A; p.Val155Met) in all three cases, consistent with a
diagnosis of the autosomal dominant condition SAVI. Functional assessment of this mutation identified a prominent
interferon signature which was confirmed on repeat testing.
Conclusions: SAVI presented in this family as ILD with early onset juvenile rheumatoid arthritis. This condition
should be considered in all rheumatoid arthritis patients with early-onset ILD and in all JIA patients with ILD.
Keywords: SAVI, Autoinflammatory, Interstitial lung disease, Interferon, Juvenile rheumatoid arthritis
Background
First described in 2014 [1], STING-associated vasculopa-
thy with onset in infancy (SAVI) is a type 1 interferono-
pathy manifesting as a pulmonary and vascular
syndrome resulting from gain-of-function mutations in
TMEM173, the gene encoding STING. To date there are
only three reports of affected families in the literature
[2–4].Here we describe a three generation kindred with
a phenotype of interstitial lung disease (ILD) and
rheumatoid factor positive (RF+) polyarticular juvenile
idiopathic arthritis (JIA), segregating as a dominant trait
due to a recurrently described V155M mutation in
STING. This report extends the SAVI phenotype and
emphasises the need to consider this diagnosis in pa-
tients with JIA or early onset rheumatoid arthritis
plus ILD.
Case presentation
The index case (case 1) is a 15-month-old Caucasian girl
born by spontaneous vaginal delivery at 28 weeks of ges-
tation, weighing 1056 g (30th centile). Her course on the
neonatal unit was unremarkable given her gestation. She
was discharged home at 3 months of age with presumed
chronic lung disease of prematurity on 0.06 L low flow
oxygen and no evidence of skin disease. She was re-
admitted 1 month later with failure to thrive and re-
spiratory difficulties. She received treatment for a lower
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respiratory tract infection with antibiotics and high flow
oxygen. She continued to deteriorate, requiring intub-
ation and ventilation at 5 months of age. Chest com-
puted tomography identified widespread ground glass
interstitial changes consistent with ILD. Lung biopsy
showed interstitial thickening with type 2 pneumocyte
hyperplasia, but genetic testing for known pathogenic
variants related to surfactant deficiency was negative. Re-
sults of her laboratory investigations are shown in
Table 1.
Case 2 is the 22-year-old mother of case 1. She was di-
agnosed with RF+ polyarticular JIA in early childhood
having initially presented with arthritis of her right knee
which progressed to polyarticular involvement that in-
cluded temporomandibular and hip joints. She was also
noted to have a livedo-type rash on her legs. Results of
her laboratory findings are shown in Table 1. She was
treated with methotrexate, then mycophenolate and
adalimumab with partial response. She achieved good
disease control with rituximab at the age of 18 years,
with no evidence of destructive arthropathy. Lung biopsy
was performed at 8 years of age due to a persistent
cough, and abnormal chest radiograph and pulmonary
function tests (details not available). ILD was diagnosed,
presumed secondary to methotrexate and JIA. ILD
remained subclinical until 14 weeks of pregnancy when
she developed increased work of breathing requiring
admission and supplemental oxygen. A pneumocystis
immunofluorescence test was negative, but she was
treated for pneumocystis jiroveci pneumonia together
with a tapering course of oral prednisolone. Post-partum
her symptoms stabilised, and her ongoing supplemental
oxygen requirement decreased.
Case 3 is the maternal grandmother of case 1. She was
diagnosed with RF+ polyarticular JIA at 16 years of age
which was initially treated with sulfasalazine, then so-
dium aurothiomalate. She subsequently developed
breathing difficulties and a dry cough. Pulmonary func-
tion tests showed a restrictive defect (transfer factor of
32% predicted). Penicillamine was substituted for
sodium aurothiomalate with subsequent respiratory
improvement. Her symptoms recurred at 35 weeks in to
her first pregnancy (Case 2). She was treated with oral
prednisolone and had a normal delivery at 40 weeks.
Respiratory symptoms resolved post-partum. ILD sec-
ondary to RA (rheumatoid arthritis) and associated
treatment was the suggested diagnosis following lung bi-
opsy. Her arthritis was subsequently treated with low
dose methotrexate then azathioprine. Her respiratory
function deteriorated again at 22 weeks gestation during
a second pregnancy. Oral and intravenous steroid treat-
ment was effective. A 3rd pregnancy was uneventful,
Table 1 Clinical and laboratory findings of cases 1–3
Case 1 Case 2 Case 3
Gender Female Female Female
Age at presentation Neonate 22months 16 years
Failure to thrive Yes Unknown Unknown
Rash No Yes Unknown
ILD Yes Yes Yes
Arthritis No Polyarticular JIA Polyarticular JIA
CRP (mg/L) 56 < 5–46 3a
Hb (g/L) 7.1 (NR 11.4–14.1) 11.1 (NR 11.5–16.5) 12.1 (NR 11.5–16.5)
C3 (g/L) 1.47 (NR 0.9–1.8) 1.65 (NR 0.75–1.65) Unknown
C4 (g/L) 0.24 (NR 0.1–0.4) 0.2 (NR 0.14–0.54) Unknown
IgG (g/L) 11.49 (NR 2.4–8.8) 26.0 (NR 6.0–16.0) 10.10 (NR 6.0–16.0)
IgA (g/L) 0.66 (NR 0.1–0.5) 3.5 (NR 0.5–2.4) 3.06 (NR 0.8–2.8)
IgM (g/L) 1.36 (NR 0.2–1.0) 2.1 (NR 0.5–1.8) 1.26 (NR 0.5–1.9)
Anti-smooth muscle Positive Negative Negative
ANA Negative 1:320 1:80/negativeb
ENA Negative Negative Negative
Anti-dsDNA (mg/L) Negative Negative 1.2
RF (IU/mL) Negative 123 797
Anti-CCP Not performed Negative Not performed
ANA Anti-nuclear antibody (NR < 1:80), Anti-CCP Anti-cyclic citrullinated peptide, Anti-dsDNA (NR < 5mg/L), Anti-smooth muscle (NR < 1:10), C Complement (< 5
mg/l), CRP C-reactive protein, ENA Extractable nuclear antigen (NR < 1:80), Hb Haemoglobin, Ig Immunoglobulin, ILD Interstitial lung disease, NR Normal range, RF
Rheumatoid factor (NR < 30 IU/mL). aOn single measurement. bFirst test was positive with value shown, second test was negative
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throughout which she was treated with 10 to 20mg oral
prednisolone daily. Due to declining lung function she
underwent single lung transplantation at the age of 30
years. She died aged 38 years from multi-organ failure
presumed secondary to lung infection, having presented
with acute respiratory failure and lower lobe opacifica-
tion of her transplanted lung. Post-mortem identified
the cause of death to be multiple organ dysfunction syn-
drome and fungal infection of the left lung.
The family history of ILD across three generations
suggested an autosomal dominant aetiology, and in the
context of JIA in cases 2 and 3, a diagnosis of coatomer
protein subunit alpha (COPA) syndrome versus SAVI
was proposed. Targeted Sanger sequencing of whole
blood DNA from cases 1 and 2 was negative for muta-
tions in COPA but identified a heterozygous TMEM173
mutation (c.463G > A; p.Val155Met) in both patients,
consistent with SAVI. DNA was subsequently extracted
from stored appendicectomy tissue from case 3 and was
shown to be positive for the same TMEM173 mutation.
RNA was extracted from peripheral whole blood from
cases 1 and 2 to functionally assess the TMEM173 muta-
tion. The expression of six interferon stimulated genes
was measured using quantitative PCR. An interferon
score, calculated by comparing the median fold expres-
sion of these genes in case 1 and 2 against their expres-
sion in 29 healthy controls, was generated as previously
described [5]. A prominent interferon signature was
identified in both cases and confirmed on repeat testing
(Fig. 1).
Following the molecular diagnosis, case 1 was treated
with 3 days of 10 mg/kg intravenous methylprednisolone
with limited clinical response followed by high oral pred-
nisolone (which was later weaned). She also received 2
g/kg monthly intravenous immunoglobulin and was
extubated onto high flow nasal cannula oxygen therapy
following several failed extubation attempts. Due to the
reported benefits of JAK1/2 inhibition in SAVI [6, 7],
case 1 commenced treatment with baricitinib 1 mg twice
daily at 8 months of age and weaned to low flow oxygen
1 month thereafter. She is currently stable from a re-
spiratory perspective with mild tachypnoea and
Fig. 1 The expression of six interferon stimulated genes (ISGs) measured in whole blood from case 1 and case 2 on two different occasions was
determined by quantitative reverse transcription PCR, and compared to the normalised data of 29 healthy controls (as described in Rice et al.
Lancet Neurology 2013:12:1159–69). Numbers in brackets represent decimalized age (years) at time of sampling followed by the interferon score
derived from the expression levels of interferon signature genes. RQ, relative quantification
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increased work of breathing. There is no evidence of
joint disease.
Case 2 remained in remission with regards to her arth-
ritis until 10 months post-partum, when she had a flare
of arthritis for which she again received rituximab. She
has since commenced baricitinib, initially at 2 mg daily
then increased to 4 mg daily, which has been well toler-
ated. She remains on 1 L per minute low flow oxygen
but reports an improvement in activities of daily living.
Her oxygen requirement is anticipated to be long-term.
Discussion
Since the term type 1 interferonopathy was first coined
in 2011 [8], a growing number of genotypes and molecu-
lar pathways have been identified which, in the mutant
state, lead to chronic upregulation of type 1 interferon
[9]. SAVI was initially reported in 2014 as a pulmonary
vascular syndrome with significant cutaneous involve-
ment [1]. More recently it has been recognised that the
associated phenotype is highly variable. The original de-
scription of SAVI is one of pulmonary, cutaneous and
vascular manifestations. More recently it has been recog-
nised that the associated phenotype is highly variable
[10] with case descriptions ranging from lethal lung in-
volvement to isolated cutaneous disease [1, 2, 4, 7, 11].
Similar to a recent SAVI case report of absent cutaneous
involvement [12], none of the cases reported here had
the typical, severe skin manifestations of the condition.
Indeed, the variable phenotypic expression reported in
familial cases [2–4] is well illustrated in our cases.
It is increasingly recognised that type 1 interferonopa-
thies can manifest as musculoskeletal disease. In 2017,
Carvalho et al reported two families demonstrating an
autosomal dominant, multisystem syndrome with pro-
gressive musculoskeletal disease which presented simi-
larly to Jaccoud’s arthropathy [13]. Affected cases carried
a heterozygous gain-of-function mutation in IFIH1 (the
gene encoding MDA5), resulting in chronic upregulation
of type 1 interferon signalling. More recently, Rodero
et al described a case of deforming arthropathy in the
context of biallelic hypomorphic mutations in DNASE2,
leading to loss of DNase II activity, an accumulation of
self-derived DNA and subsequent type 1 interferon pro-
duction [14]. Arthritis (including RF+ arthritis), arthral-
gia and myalgia have previously been described in the
SAVI literature. However, when present, these features
have generally been reported as minor features of the
condition [1–3, 7]. To our knowledge this family is ap-
parently so-far unique, whereby SAVI presented as a
non-destructive, non-deforming RF+ polyarticular JIA in
the two older cases. It remains to be seen whether the
proband will also manifest arthritis while receiving a
JAK1/2 inhibitor.
Conclusion
ILD is commonly associated with connective tissue dis-
orders and their treatments [15]. However, ILD present-
ing in three generations of the same family in the
context of RF+ polyarticular JIA triggered investigation
for an underlying autosomal dominant cause. A unifying
diagnosis of SAVI has allowed more targeted therapy
and significantly altered disease counselling for this fam-
ily. Thus, this report highlights the need for physicians
to revisit the diagnoses of patients with complex, atypical
or treatment-resistant disease. We urge rheumatology
and respiratory physicians to consider a type 1 interfero-
nopathy in patients with JIA/early onset RA plus ILD.
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